Ruangsiriluk, W.; Deshpande, M.; Boukharov, N.; Rajarshi, G.; Mukherji, S.; Yuan, S.; Wiseman, J.; Chen, N.; Park, E.; Cho, H.;
et al. Reversing Pathology in an Aggravated Fabry Mouse Model Using Low-Dose Engineered Human Alpha-Galactosidase A AAV Gene Therapy. Biomedicines 2025, 13, 577.
https://doi.org/10.3390/biomedicines13030577
AMA Style
Ruangsiriluk W, Deshpande M, Boukharov N, Rajarshi G, Mukherji S, Yuan S, Wiseman J, Chen N, Park E, Cho H,
et al. Reversing Pathology in an Aggravated Fabry Mouse Model Using Low-Dose Engineered Human Alpha-Galactosidase A AAV Gene Therapy. Biomedicines. 2025; 13(3):577.
https://doi.org/10.3390/biomedicines13030577
Chicago/Turabian Style
Ruangsiriluk, Wanida, Mugdha Deshpande, Natalia Boukharov, Girija Rajarshi, Shreya Mukherji, Shipeng Yuan, Jennifer Wiseman, Nancy Chen, Eric Park, Hyelim Cho,
and et al. 2025. "Reversing Pathology in an Aggravated Fabry Mouse Model Using Low-Dose Engineered Human Alpha-Galactosidase A AAV Gene Therapy" Biomedicines 13, no. 3: 577.
https://doi.org/10.3390/biomedicines13030577
APA Style
Ruangsiriluk, W., Deshpande, M., Boukharov, N., Rajarshi, G., Mukherji, S., Yuan, S., Wiseman, J., Chen, N., Park, E., Cho, H., & Islam, R.
(2025). Reversing Pathology in an Aggravated Fabry Mouse Model Using Low-Dose Engineered Human Alpha-Galactosidase A AAV Gene Therapy. Biomedicines, 13(3), 577.
https://doi.org/10.3390/biomedicines13030577
